NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Hester Biosciences Proposes Re-appointment of Rajiv Gandhi as CEO & MD for 3 Years
Hester Biosciences has initiated a postal ballot process to seek shareholder approval for the re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director. The proposed tenure is for three years, spanning from April 1, 2026, to March 31, 2029. This move is intended to ensure leadership continuity, and the resolution is being proposed as a Special Resolution. Shareholders can participate in the remote e-voting process from February 8 to March 9, 2026.
முக்கிய அம்சங்கள்
Proposed re-appointment of Mr. Rajiv Gandhi as CEO & Managing Director for a 3-year term.The new term is scheduled to run from April 1, 2026, through March 31, 2029.Remote e-voting period is set for February 8, 2026, to March 9, 2026, with results by March 11.The resolution requires approval as a Special Resolution via postal ballot.The cut-off date for shareholder eligibility was fixed as January 30, 2026.
👀 கவனிக்க வேண்டியவை
This is a routine leadership continuity event for the promoter-led company. Investors should support the resolution to maintain management stability, though no immediate impact on stock price is expected.
Hester Biosciences Q3 FY26: PAT Surges 140% YoY; H9N2 Vaccine License Received
Hester Biosciences reported a strong 140% YoY increase in standalone PAT for Q3 FY26, driven by a favorable product mix and cost discipline. While the Poultry Healthcare division grew by 32% in Q3, the Animal Healthcare division saw a 38% decline due to timing delays in government-led immunization programs. The company achieved a major regulatory milestone by receiving manufacturing licenses for the H9N2 Avian Influenza vaccine and successfully capitalized its fill/finish facility, doubling its drug product capacity.
முக்கிய அம்சங்கள்
Standalone PAT increased by 140% YoY in Q3 FY26, supported by improved operational discipline.Poultry Healthcare division revenue grew 32% in Q3 and 17% over the 9-month period.Received marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine post-quarter end.Capitalized a new fill/finish facility from the INR 182 crore CWIP, doubling drug product capacity.Animal Healthcare revenue declined 38% in Q3 due to tender delays, with recovery expected in Q4 FY26.
👀 கவனிக்க வேண்டியவை
Investors should focus on the upcoming launch of the H9N2 vaccine and the resumption of government immunization tenders in Q4. The doubling of manufacturing capacity positions the company for significant scale-up in both domestic and export markets.
Hester Biosciences Q3 Standalone PAT Jumps 140% to ₹106.7M; Poultry Division Grows 32%
Hester Biosciences reported a robust standalone performance for Q3 FY26, with PAT surging 140% YoY to ₹106.69 million on a 12% revenue increase. The growth was primarily driven by the Poultry Healthcare division, which grew 32%, while the Animal Healthcare division faced a 38% decline due to delayed government tenders. Consolidated PAT for the quarter fell 18% to ₹93.10 million, largely due to losses in the African subsidiary. However, the company has doubled its drug product capacity and expects a strong Q4 as national immunization programs resume.
முக்கிய அம்சங்கள்
Standalone Q3 PAT rose 140% to ₹106.69 million, while standalone revenue grew 12% to ₹703.54 million.Poultry Healthcare division delivered 32% growth in Q3, supported by a new H9N2 Avian Influenza vaccine license.Animal Healthcare revenue declined 38% due to deferred government orders, which are scheduled to commence in February 2026.Consolidated 9M FY26 PAT stands at ₹409.37 million, representing a 50% growth over the previous year.Capitalized a new fill-finish facility during the quarter, effectively doubling the company's drug product capacity.
👀 கவனிக்க வேண்டியவை
Investors should view the standalone margin expansion and poultry segment growth as positive indicators of operational efficiency. The temporary dip in animal healthcare revenue is expected to reverse in Q4, making the current performance a strong base for year-end results.
Hester Biosciences Q3 Standalone PAT Surges 140% YoY to ₹106.7 Mn; CEO Re-appointed
Hester Biosciences delivered a robust standalone performance for Q3 FY26, with Net Profit jumping 140% YoY to ₹106.69 million. Standalone revenue grew by 12% YoY, driven primarily by a 32% growth in the Poultry Healthcare segment. However, consolidated PAT declined by 18% YoY to ₹93.10 million, largely due to a sharp reduction in 'Other Income' compared to the previous year. The board also confirmed the re-appointment of founder Rajiv Gandhi as CEO and Managing Director for a three-year term starting April 2026.
முக்கிய அம்சங்கள்
Standalone Revenue from Operations increased 12% YoY to ₹703.54 million in Q3 FY26.Standalone Net Profit (PAT) rose 140% YoY to ₹106.69 million from ₹44.39 million.Poultry Healthcare segment revenue grew 32% YoY to ₹513.02 million.Consolidated PAT fell 18% YoY to ₹93.10 million, impacted by lower other income of ₹6.69 million vs ₹78.09 million YoY.Mr. Rajiv Gandhi re-appointed as CEO & Managing Director for 3 years effective April 1, 2026.
👀 கவனிக்க வேண்டியவை
Investors should take note of the strong operational recovery in the standalone business and the significant growth in the poultry segment. The re-appointment of the founder-CEO ensures leadership continuity, making the stock a 'Watch' for sustained margin improvement.
Hester Biosciences Receives Manufacturing License for H9N2 Avian Influenza Vaccine
Hester Biosciences has received a manufacturing license from the Food & Drugs Control Administration for its Low Pathogenic Avian Influenza (H9N2) vaccine for poultry. The H9N2 strain is a persistent challenge in the poultry industry, causing significant economic losses through reduced egg production and broiler performance. This vaccine was developed using technology acquired from ICAR-NIHSAD via Agrinnovate India. This regulatory milestone strengthens Hester's poultry healthcare portfolio and addresses a year-round comorbidity issue in the sector.
முக்கிய அம்சங்கள்
Received manufacturing and marketing license from FDCA for Inactivated Avian Influenza H9N2 vaccine.Technology for the vaccine was acquired from ICAR-NIHSAD through Agrinnovate India.Targets the H9N2 strain which causes significant economic losses in both layer and broiler poultry segments.The vaccine aims to prevent irreversible drops in egg production and high mortality rates associated with the virus.Strengthens the company's prevention-led poultry healthcare product pipeline.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that expands Hester's product offerings in the animal healthcare market. Monitor the commercial launch timeline and the subsequent impact on the poultry segment's revenue growth.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Ester Industries JV Awards Engineering Contract to Toyo for 70,000 MT PET Recycling Plant
Ester Industries' joint venture, ELITe, has awarded a detailed engineering contract to Toyo Engineering India for its 'Infinite Loop India' project in Bharuch, Gujarat. The facility is designed to produce 70,000 metric tonnes of PET resin annually, targeting the packaging and textile sectors. The project has already secured Nike as an anchor customer through a multi-year offtake agreement and is on track for completion by the end of 2027. Financial health remains strong with USD 5 million in land acquisition savings and multiple debt financing term sheets received from international lenders.
முக்கிய அம்சங்கள்
Awarded detailed engineering contract to Toyo Engineering India for the 70,000 MT annual capacity PET recycling plantProject construction is projected for completion by the end of 2027 in Bharuch, GujaratSecured Nike as a multi-year anchor customer, providing high commercial visibilityRealized USD 5 million in savings from land acquisition, ensuring the project remains on budgetDebt financing process is on schedule with multiple term sheets received from international lenders
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant de-risking milestone for Ester's high-growth circular economy segment. Monitor the commencement of construction and further offtake agreements as the 2027 deadline approaches.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
